Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - exenatide, quantity: 250 microgram/ml - injection, solution - excipient ingredients: sodium acetate; water for injections; metacresol; glacial acetic acid; mannitol - exenatide is indicated as adjunctive therapy to improve glycaemic control in patients with type 2 diabetes mellitus who are taking metformin, a sulfonylurea, or a combination of metformin and a sulfonylurea, or a combination of metformin and a basal insulin, but are not achieving adequate glycaemic control.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - exenatide, quantity: 250 microgram/ml - injection, solution - excipient ingredients: sodium acetate; metacresol; glacial acetic acid; mannitol; water for injections - exenatide is indicated as adjunctive therapy to improve glycaemic control in patients with type 2 diabetes mellitus who are taking metformin, a sulfonylurea, or a combination of metformin and a sulfonylurea, or a combination of metformin and a basal insulin, but are not achieving adequate glycaemic control.

Filipīnas - angļu - FDA (Food And Drug Administration)

astrazeneca pharmaceuticals (phils.), inc. - byetta® - solution for injection (sc) - 250 mcg/ml (5mcg/dose)

Singapūra - angļu - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - exenatide - injection, solution - 250mcg

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

astrazeneca uk ltd - exenatide - solution for injection - 250microgram/1ml

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

astrazeneca uk ltd - exenatide - solution for injection - 250microgram/1ml

Kanāda - angļu - Health Canada

astrazeneca canada inc - exenatide - solution - 5mcg - exenatide 5mcg - incretin mimetics

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

astrazeneca limited - exenatide 250 µg/ml;   - solution for injection - 10µg/40µl - active: exenatide 250 µg/ml   excipient: glacial acetic acid mannitol metacresol sodium acetate trihydrate water for injection - adjunctive therapy to improve glycaemic control in patients with type 2 diabetes mellitus who are taking metformin, a sulfonylurea, or a combination of metformin and a sulfonylurea but are not achieving adequate glycaemic control. to improve glycaemic control in patients with type 2 diabetes mellitus in combination with a basal insulin with or without metformin and/or a thiozolidinedione.

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

astrazeneca limited - exenatide 250 µg/ml;   - solution for injection - 5µg/20µl - active: exenatide 250 µg/ml   excipient: glacial acetic acid mannitol metacresol sodium acetate trihydrate water for injection - adjunctive therapy to improve glycaemic control in patients with type 2 diabetes mellitus who are taking metformin, a sulfonylurea, or a combination of metformin and a sulfonylurea but are not achieving adequate glycaemic control. to improve glycaemic control in patients with type 2 diabetes mellitus in combination with a basal insulin with or without metformin and/or a thiozolidinedione.

Filipīnas - angļu - FDA (Food And Drug Administration)

astrazeneca pharmaceuticals (phils.), inc. - byetta® - solution for injection (sc) - 250 mcg/ml (10 mcg/dose)